No automatic approval of post-market changes to biologics in India
This article was originally published in SRA
Executive Summary
The Indian drug regulatory agency, the Central Drugs Standard Control Organization, has done away with a provision that allowed manufacturers of biological drugs to obtain default clearance of post-approval changes to their products if the agency did not respond to valid applications within a specific time period1,2.